Docket No.: 0365-0670PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Soili PELTONEN et al.

Application No.: 10/573,041 Confirmation No.: 4395

Filed: March 22, 2006

Art Unit: N/A

For: PIGMENT AND FILLER AND A METHOD OF Examiner: Not Yet Assigned

MANUFACTURING IT

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL

(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE LI14 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

a. Copies of cited U.S. patents and patent application publications are not included.
 Copies of foreign patent documents and non-patent literature are included.

Brch, Stewart, Kolasch & Birch, LLP GMM/TK/enm

Docket No : 0365-0670PUS1 Application No.: 10/573,041 Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. \$1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120: U.S. Appl. No(s) and U.S. Filing Date ш CONCISE EXPLANATION OF THE RELEVANCE (check at least one box) X DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3). OTHER - The following additional information is provided for the Examiner's

consideration

of a new patent application; therefore, no fee is required. b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required. c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required (This section is not to be used with RCE's.) d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required. e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required. f. This Information Disclosure Statement is being filed before the mailing date of first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the even that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(c) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p). g. This Information Disclosure Statement is being filed before the mailing date of Final Office Action under 37 C.F.R. § 1.131 (See 37 C.F.R. § 1.97(c)(2)).	IV.	FEES	(check one box)
a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required c. This Information Disclosure Statement is being filed within three months of th filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required (This section is not to be used with RCE's.) d. This Information Disclosure Statement is being filed within three months of th date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required. e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required. Ø f. This Information Disclosure Statement is being filed before the mailing date of first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the even that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p). g. This Information Disclosure Statement is being filed before the mailing date of Final Office Action under 37 C.F.R. § 1.131 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).	☐ of a ne		This Information Disclosure Statement is being filed concurrently with the filing at application; therefore, no fee is required.
filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required (This section is not to be used with RCE's.) d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required. e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required. f. This Information Disclosure Statement is being filed before the mailing date of first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the even that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p). g. This Information Disclosure Statement is being filed before the mailing date of Final Office Action under 37 C.F.R. § 1.131 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).	a conti		This Information Disclosure Statement is being filed concurrent with the filing of -in-part, continuation, or divisional patent application; therefore, no fee is required.
date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required. c. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required. f. This Information Disclosure Statement is being filed before the mailing date of first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the even that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p). g. This Information Disclosure Statement is being filed before the mailing date of in Final Office Action under 37 C.F.R. § 1.131 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).		date of	
of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee of statement is required. It is from the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. It is that a first Office Action on the merits has been issued, please consider this DS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p). If is Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.13 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.31 (See 37 C.F.R. § 1.97(c)(2)).		f entry o	-
first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the even that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).		Request	
Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).	first A that a	ction or first Off (c) and	ace Action on the merits has been issued, please consider this IDS under 37 C.F.R. see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been
No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached. or		Office A	te of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

GMM/TK/enm

prior to the filing of this statement.

Application No.: 10/573,041 Docket No.: 0365-0670PUS1

VI. PAYMENT OF FEES (check one box)

The required fee is listed on the attached Fee Transmittal.

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fore.

Dated: December 22, 2006

Respectfully submitted,

Registration Np. 128,977 BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road Suite 100 East P.O. Box 747

Falls Church, Virginia 22040-0747 (703) 205-8000

Attorney for Applicant

Attachment(s):

Attachment(s):

PTO-SB08
Documents
Foreign Search Report
Fee
Other:

GMM/160enm

PTC/SB/86AB (99-26)
Approved for use through 03/31/2007. OM8 9851-6031
U.S. Palani and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Substitute for from 1645/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/573,041-Conf. #4395	
				Filling Date	March 22, 2006	
				First Named Inventor	Soili PELTONEN	
				Art Unit	N/A	
(Use as many sheets as necessary)			s necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Adomey Docket Number	0365-0670PUS1	

U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Relevant Passages or Relevant Figure Appear Cite Document Number Publication Date MM-DD-YYYY Name of Patentee or Number-Kind Code² (Elenown Applicant of Cited Door No 06-04-2003 Malkki et al. 04-09-2002 Peltonene et al. 08-12-2003 Lammers et al. AA* US-6,582,509-B2 AB* US-6,369,215-B1 AC* US-6,605,715-B1 AD* US-6,605,459-B1

		FORE	GN PATENT D	OCUMENTS		_
Examiner Initials*	Cite No.	Foreign Patent Cocument	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ¹ -Humber ⁴ -Kind Code ⁵ (Fixecen)	MM-DD-YYYY	Applicant of Clied Document		7*
	BA	EP-0784119-A1	07-16-1997			Г
	BB	EP-1254939-A1	11-06-2002			П
	BC	WO-00/69916-A1	11-23-2000			г

05-13-2003 Bengs et al.

"SUMPLES what is represe survivants whether and cables in an administration will all \$60 persons. Due to through this fire all to information and in the contract to the contr

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published,	T²	
	CA	WOLFF et al., The acylation of Com Starch, Amylose and Amylopectin, J. Amer. Chem. Soc., Vol. 73, pp. 346-349, (1952).		
	CB	GROS et al., Properties of Fatty Acid Esters of Amylose, J. Amer. Oil Chemists' Soc., Vol. 39, pp. 19 - 24, (1962).	Г	
	cc	Papermaking Science and Technology, Book Part 11, p. 65.	$\overline{}$	

"EXAMINER, Initial if reference considered, whether or not citation is in confi considered. Include copy of this form with next communication to applicant. axes with MPEP 609. Draw line through citation if not in conformance and not

'Applicant's unique citation designation number (optional). "Applicant is to place a check mark here it English language Translation is attached

Examiner Stansture	Date Considered	1
Birch, Stewart, Kolasch & Birch, LLP	GMM/Tik/en	m